Since 2006, the US Food and Drug Administration, Congress, and other policymakers have explored the appropriate way to guarantee the clinical and analytical validity of laboratory-developed tests. In the past, the Association for Molecular Pathology has publicly urged the Food and Drug Administration to exercise caution in implementing regulatory changes that could potentially hinder innovation or interfere with the practice of medicine. In 2012, the Association for Molecular Pathology Professional Relations Committee chose to develop this paper with the goal of outlining the best methods for ensuring appropriate oversight and validation of molecular diagnostic procedures. At the conclusion of this process, the workgroup reaffirmed the Association's previous position that the Centers for Medicare and Medicaid Services Clinical Laboratory Improvement Amendments program can provide the appropriate level of oversight for the vast majority of diagnostic tests. Copyright Copyright © 2014 American Society for Investigative Pathology. 2014 American Society for Investigative Pathology.
Ferreira-Gonzalez, A., Emmadi, R., Day, S. P., Klees, R. F., Leib, J. R., Lyon, E., … Klein, R. D. (2014). Revisiting oversight and regulation of molecular-based laboratory-developed tests: A position statement of the association for molecular pathology. Journal of Molecular Diagnostics, 16(1), 3–6. https://doi.org/10.1016/j.jmoldx.2013.10.003